Kornimate/medical-research-clean huggingface dataset:
the value of bio-electrical impedance analysis in irritable bowel syndrome

Conditions: Irritable Bowel Syndrome

Summary: the study aim is to investigate the bio-electrical impedance (bia) parameters in general, and phase angle (pha) in particular in irritable bowel syndrome (ibs) patients and to compare these with values from healthy controls, while assessing the relationship with other confounding parameters in ibs: psychological parameters, physical activity, dietary pattern (with special interest in fodmap intake). in a second phase, the evolution of the bia parameters will be analyzed according to response to therapy.

the role and significance of bio-electrical impedance analysis (bia) has not been studied in ibs. therefore, the investigators designed this exploratory study to assess its potential role in the diagnosis and follow-up of treatment in ibs. the study aim is to investigate the bia parameters in general, and pha in particular in ibs patients and to compare these with values from healthy controls, while assessing the relationship with other confounding parameters in ibs: psychological parameters, physical activity, dietary pattern (with special interest in fodmap intake). in a second phase, the evolution of the bia parameters will be analyzed according to response to therapy. the primary objective is to compare the bia parameters including pha between ibs and healthy individuals.

Eligibility criteria:
inclusion criteria: * patients aged 18 - 75 years; * fulfilling the rome iv criteria for ibs (only for patients); exclusion criteria: * clinical suspicion of an organic disorder different from ibs (patients can be included when this disorder had been excluded); * known inflammatory bowel disorder; * known major intestinal motility disorder; * alcohol (defined as more than 14 u per week) or other substance abuse; * active psychiatric disorder; * known systemic or auto-immune disorder with implication for the gi system; * prior abdominal surgery (with the exception of cholecystectomy or ap-pendectomy); * any prior diagnosis of cancer other than basocellular carcinoma; * current chemotherapy; * history of gastro-enteritis in the past 12 weeks; * dietary supplements unless taken at a stable dose for more than 12 weeks; * treatment with neuromodulators (one neuromodulator taken at a sta-ble dose for more than 12 weeks is allowed); * pregnancy.
efficacy of isst in schizophrenia

Conditions: Schizophrenia

Summary: the isst study investigates whether integrated social cognitive remediation and social behavioral skills therapy is more efficacious in improving functional outcome and treatment adherence than an active control treatment comprising drill-and-practice oriented neurocognitive remediation.

deficits in social functioning are a defining, very burdening feature of schizophrenia precluding patients from participating in a satisfying life. traditional drug and psychosocial therapy and available specific treatment strategies that directly target single key determinants of functional outcome like neurocognition, social cognition, and social behavioral skills have produced only moderate effects leaving an urgent need for further optimization. the present trial aims to more efficaciously improve functional outcome by integrating social behavioral and social cognitive treatment strategies. six months of "integrated social cognitive and behavioral skills therapy (isst)" will be compared with "neurocognitive remediation therapy (ncrt)" as active control condition in a randomized multicenter clinical trial using a two group pre-post design with 2x90 patients in the remitted early phase of schizophrenia. beyond "all-cause-discontinuation" as common primary outcome of all clinical trials of the esprit-consortium, measures of functional outcome and subjective quality of life, patient experience as well as neurocognitive, social-cognitive and social behavioral measures will be assessed at baseline (v0), after completion of treatment (v6), and after 6 months follow-up (v12). isst is expected to reduce the one-year discontinuation rate by 20% compared with ncrt, and to be superior in functional outcome measures by an effect size of at least d=0.42.

Eligibility criteria:
inclusion criteria: * written informed consent * dsm-iv-tr diagnosis of schizophrenia (295.10-30, 295.90) * panss at baseline: total score ≤ 75 * proficiency in german language. exclusion criteria: * lack of accountability * positive urine drug-screening for illicit drugs at screening (except cannabinoids and benzodiazepines) * serious suicidal risk at screening visit * other relevant axis 1-diagnoses according to diagnostic interview (mini); * other relevant neurological or somatic disorders * verbal iq\<80 (mwt-b)

Keywords: social cognition social skills cognitive remediation functional outcome treatment adherence
the effect of reflexology on pain, comfort and breastfeeding self-efficacy

Conditions: Reflexology

Summary: this study was conducted to determine the effects of reflexology applied to mothers with headache due to spinal anesthesia after cesarean delivery on pain, comfort and breastfeeding self-efficacy levels. the study, which was conducted with a single-blind, randomized controlled experimental design, was conducted between april 2024 and august 2024 at the department of obstetrics and pediatrics, sbu van training and research hospital with mothers who had cesarean delivery under spinal anesthesia and had postpartum headache (intervention group=30, control group=30). foot reflexology was applied to the mothers in the intervention group for a total of 30 minutes, 15 minutes on each foot. the control group was not subjected to any intervention other than routine nursing practices. personal information form, visual analog scale (vas), postpartum comfort scale (ppsc) and breastfeeding self-efficacy scale (bsse) were used as data collection tools.


Eligibility criteria:
inclusion criteria: * 18 years and older, * performing sd under spinal anesthesia, * experiencing postpartum headaches, * caesarean section performed at 37-42 weeks of gestation, * giving only one live birth, * open to written or oral communication, * at least a primary school graduate, * no complications during pregnancy, * mothers who agreed to participate in the study exclusion criteria: * performing a cesarean section at periods other than 37-42 weeks of gestation, * caesarean section under general anesthesia, * have health problems such as fractures, dislocations, phlebitis, arthritis, burns, wounds, eczema, fungus or inflammation in the foot tissue, * with disease of the cardiovascular system, * with chronic diseases such as hypertension or diabetes mellitus, * postpartum controlled analgesia administered, * mothers with psychiatric diagnoses such as anxiety and depression
evaluation of safety of sparc0913 in open angle glaucoma or ocular hypertension

Conditions: Open Angle Glaucoma; Ocular Hypertension

Summary: the purpose of this study is to evaluate the long-term safety of sparc0913. a multicenter, open label, non-randomized, uncontrolled, single group assignment, safety study of subjects with primary open angle glaucoma or ocular hypertension is planned. subjects will receive study medication for a period of 24-weeks.

this is a multicenter, open label, non-randomized, single-arm, extension safety study to evaluate the long-term safety of sparc0913. subjects who completed the prior evaluator-masked clinical non-inferiority study participated in the current study.

Eligibility criteria:
inclusion criteria: * men and women aged ≥18 years * willing to participate and giving written informed consent * willing to commit to study medication-dosing, study visits and follow-up visits to complete evaluation * eligible to receive latanoprost once a daily as monotherapy for treatment of glaucoma exclusion criteria: * history of allergic hypersensitivity or poor tolerance to latanoprost * history of substance abuse or addiction (alcohol drugs) in the past 3 years * history of chronic use of concomitant medications in neurologic or psychiatric illness that would affect assessment of safety and effectiveness of the study medication * any abnormality preventing iop measurement

Keywords: glaucoma ocular hypertension
antihypertensive treatment in masked hypertension

Conditions: Masked Hypertension

Summary: the primary purpose of the study is to estimate the target organ protection after 12 months of antihypertensive treatment in masked hypertension patients with at least one kind of target organ damage (left ventricular hypertrophy, large arterial stiffness and microalbuminuria). improvement was defined as the relevant parameter back to normal or declined at least 20%. the secondary objectives include: blood pressure lowering effect, target organ damage parameters improvement, and the incidence rate of all cause death and cardiovascular events (stroke and myocardia infraction).


Eligibility criteria:
inclusion criteria: 1. age 30-70 years old 2. masked hypertension patients, defined as clinic bp\<140/90 mmhg, while 24h ambulatory bp ≥130/80 mmhg and (or) daytime bp ≥135/85 mmhg and (or) nighttime bp ≥120/70 mmhg 3. combined with at least one kind of target organ damage: left ventricular hypertrophy (cornell voltage combination ≥2440mm·ms or sokolow-lyon index ≥4.0mv for male and 3.5mv for female), large arterial stiffness (brachial-ankle pulse wave velocity ≥1400cm/s) and microalbuminuria (twice random urine microalbuminuria/creatinine ratio ≥2.5mg/mmol for male and 3.5mg/mmol for female). 4. didn't use any anti-hypertension drugs within 2 weeks 5. be willing to participate in the trials and able to finish clinic visits exclusion criteria: 1. under antihypertensive treatment 2. secondary hypertension 3. taking other medications that may influence bp 4. sleep apnea syndrome 5. diabetes combined with microalbuminuria 6. renal parenchymal disease, such as chronic nephritis, polycystic kidney 7. occurrence of coronary heart disease, myocardial infraction or stroke within 6 months 8. structural heart disease, such as hypertrophic cardiomyopathy, dilated cardiomyopathy 9. alanine transaminase (alt), aspartate transaminase (ast), total bilirubin (tbl) upper the twice of normal range, serum creatinine (scr)≥2.0mg/dl, plasma hypokalemia≥5.5mmol/l, 10. patients have contraindications to angiotensin receptor blockers (arbs)

Keywords: allisartan isoproxil left ventricular hypertrophy large arterial stiffness microalbuminuria
comparison of monodose and multidose presentations of gsk biologicals' hepatitis b vaccine in terms of immune response

Conditions: Hepatitis B

Summary: gsk biologicals' currently licensed multidose hepatitis b vaccine will be compared to the currently licensed monodose hepatitis b vaccine in a population with well documented hepatitis b immunological response to the vaccine (belgium).

randomized study with two groups. one group will receive gsk's multidose hepatitis b vaccine and the other group will receive gsk's monodose hepatitis b vaccine

Eligibility criteria:
inclusion criteria: * a male or female \>= 18 years of age * written informed consent obtained from the subject. * free of obvious health problems as established by medical history and clinical examination before entering into the study. * if the subject is female, she must be of non-childbearing potential, i.e. either surgically sterilized or one year post-menopausal; or, if of childbearing potential, she must be abstinent or have used adequate contraceptive precautions for 30 days prior to vaccination, have a negative pregnancy test and must agree to continue such precautions for two months after completion of the vaccination series. exclusion criteria: * use of any investigational or non-registered drug or vaccine other than the study vaccine during the study period. * chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose. (for corticosteroids, this will mean prednisone, or equivalent, greater than or equal to 0.5 mg/kg/day. inhaled and topical steroids are allowed.) * planned administration/ administration of a vaccine not foreseen by the study protocol within 30 days of the first dose of vaccine. * previous vaccination against hepatitis b * history of hepatitis b infection * known exposure to hepatitis b within the previous 6 weeks * any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (hiv) infection. * a family history of congenital or hereditary immunodeficiency. * history of allergic disease or reactions likely to be exacerbated by any component of the vaccine(s). * acute disease at the time of enrolment. (acute disease is defined as the presence of a moderate or severe illness with or without fever. all vaccines can be administered to persons with a minor illness such as diarrhoea, mild upper respiratory infection with or without low-grade febrile illness, i.e. oral temperature \< 37.5°c (99.5°f) / axillary temperature \<37.5°c (99.5°f). * acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests. * administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period. pregnant or lactating female. * female planning to become pregnant or planning to discontinue contraceptive precautions during the study period.
the effect of yoga on nerve pain caused by chemotherapy (chemotherapy-induced peripheral neuropathy)

Conditions: Chemotherapy-induced Peripheral Neuropathy; Nerve Pain; Neuropathy; Neuropathy, Painful; Pain; CIPN - Chemotherapy-Induced Peripheral Neuropathy; Chronic Pain

Summary: the purpose of this study is to test whether yoga can reduce nerve pain caused by cancer treatment (chemotherapy-induced peripheral neuropathy, or cipn). participants will take one of three approaches: * yoga classes * educational sessions on the causes and impacts of cipn, how yoga may help with cipn, and how different therapies may help with cipn * usual care with standard-of-care medications for cipn the researchers will compare how these different approaches affect participants' balance, their risk of falls, and their quality of life. this study will also measure how much yoga can help the reduced sense of touch caused by cipn. the functional assessments tug and cts can be safely completed either virtually and in-person and will be mandatory for all patients. the functional assessment frt and qst assessments that can only be completed in-person are optional at these time points.


Eligibility criteria:
inclusion criteria: * english-proficient men and women aged ≥18 years * free of oncologic disease or or stable disease by clinical examination and history * completed neurotoxic chemotherapy such as platinum agents, taxanes, vinca alkaloids, and bortezomib at least three months prior to enrollment * diagnosis of cipn based on symptom history, loss of deep tendon reflexes, or the presence of symmetrical stocking-glove pain, numbness, or paresthesia grade ≥1 sensory pain based on the nci common terminology criteria for adverse events (ctcae) version 5.0 * self-reported moderate to severe cipn pain, as defined by a score of 4 or greater on the bpi-sf average pain item over the past week * on a stable regimen (no change in three months) if taking anti-neuropathy or other pain medications and not taking acetyl-l-carnitine 77 * willing to adhere to requirement that no new pain medication be taken throughout the first 12 weeks of the study period * willing to adhere to all study-related procedures, including randomization to one of the three arms * patient answers "yes" to at least one factor in the question: "do you think your balance, gait, posture, alignment, or flexibility has been affected by your experience of cipn?" exclusion criteria: * patients who have received physical therapy or practiced yoga for cipn in the past 3 months. as patients who have received physical therapy or practiced yoga in this time period may already be experiencing its benefits, we will exclude such patients.

Keywords: yoga chemotherapy-induced peripheral neuropathy neuropathic pain pain management dana-farber cancer institute memorial sloan kettering cancer center cancer survivor cipn
sns to increase hiv testing uptake and linkage to double cascade services among adolescent msm and tgw in thailand

Conditions: Social Network Strategy; HIV Self Testing; Men Who Have Sex With Men

Summary: unaids aims to end aids by 2030 using "90-90-90" diagnosis-treatment-viral suppression targets. thailand has achieved elimination of hiv mother-to-child transmission, but continues to see new infections among adolescent men who have sex with men (ymsm) and transgender women (ytgw). reaching and engagement of key populations to hiv services remains a major challenge, with differentiated care needed to address this. investigators propose a study on outreach for hiv at-risk adolescents using peer-led social network strategies (sns), linkage to facility-based hiv self-testing, and same day hiv prevention or treatment. the study will focus on the 15-19 year age group who have the highest hiv incidence in thailand (6.9-10 per 100 person years, py), but will also include young adults aged 20- 24 years of age, due to their frequently intertwining sex networks and very similar hiv incidence of 4.9-7.2 per 100 py. eight hundred adolescent and young adult (aya) msm and tgw aged between 15-24 years will be recruited into a double hiv cascade care system. aya aged between 15-24 years will be trained as recruiters to approach and refer their peers, 'network members' (nms) to our adolescent clinic. nms will be offered a choice of either blood-based or oral fluid-based hiv self-testing. hiv positive cases will be offered same-day antiretroviral therapy (sdart) and high-risk adolescents will be offered same day preexposure prophylaxis (prep). the project will be conducted at adolescent differentiated care services previously established by cipher grants in thailand, located at king chulalongkorn memorial hospital (kcmh), bangkok. it will inform both thailand and other asia-pacific region countries with similar epidemic patterns through an implementation research lens on strategies to engage ymsm and ytgw into hiv services, which investigators believe will make high-impact contributions to our collective ultimate goal of ending aids.


Eligibility criteria:
recruiters inclusion criteria: * ages 15-24 years * assigned male gender at birth * self-defined gender identity of either msm or tgw * any one of the following: living with hiv, using hiv pre-exposure prophylaxis, receiving intermittent hiv testing for ongoing hiv risk * good rapport with king chulalongkorn memorial hospital (kcmh) adolescent health clinic, knowledgable on hiv and comfortable discussing hiv with peers network members inclusion criteria: * ages 15-24 years * assigned male gender at birth * self-defined gender identity of either msm or tgw * self-reported oral and/or anal sex with a man in the past 12 months and at risk of hiv infection (multiple sex partners in the preceding 6 months and/or inconsistent condom use) * no history of hiv testing or last hiv test \> 3 months prior to study entry exclusion criteria: * known to be living with hiv
effect of intracameral steroids during phacoemulsification on the cornea

Conditions: Corneal Edema

Summary: prospective, interventional case control study. sixty-nine eyes were randomized into 3 groups, 23 eyes each : 2groups received intracameral dexamethasone and triamcinolone (ta) respectively, while controls didn't receive any intraoperative steroids. intracameral steroids at the conclusion of phacoemulsification significantly improved corneal edema and spared corneal endothelium.

purpose: investigating the effect of intracameral steroids at the end of phacoemulsification on corneal edema and endothelial count. methods: prospective, interventional case control study. sixty-nine eyes were randomized into 3 groups, 23 eyes each : 2groups received intracameral dexamethasone and triamcinolone (ta) respectively, while controls didn't receive any intraoperative steroids. on the first postoperative day corneal edema in control compared to dexamethasone and ta groups respectively. one month later, the mean increase of corneal thickness in control compared to intracameral dexamethasone and ta groups, respectively. mean endothelial cell loss in control compared to intracameral dexamethasone and ta groups respectively.

Eligibility criteria:
inclusion criteria: * cataract grades 2 to 5 nuclear cataract (locs iii scale) * uneventful phacoemulsification operation exclusion criteria: * extremely hard cataract grade 6 nuclear cataract (locs iii scale) * soft cataract * subluxated lenses or zonular dehiscence * associated ocular pathology such as glaucoma * any signs of uveitis * trauma * retinal detachment * vitrectomized or silicone filled eyes * corneal disease such as fuch's dystrophy, corneal opacity * previous refractive corneal surgery * cases that developed ruptured posterior capsule and vitreous loss * those lost to follow up were excluded and randomly replaced by the next chronological patient
bioinformation therapy for liver cancer

Conditions: Liver, Cancer of, Non-Resectable

Summary: the aim of this study is the synergistic effect of cancer ablation and life information rehabilitation therapy on unresectable liver cancer.

by enrolling patients with unresectable liver cancer adapted to enrolled criteria, this study will document for the first time the synergistic effect of cancer ablation and life information rehabilitation therapy. the efficacy will be evaluated according to local relief degree, progress free survival (pfs) and overall survival (os).

Eligibility criteria:
inclusion criteria: * all standard therapies have failed according to nccn guidelines or the patient refuses standard therapies * body tumor 1-6, with at least one tumor length \> 2 cm * kps ≥ 70, lifespan \> 6 months * platelet count ≥ 80×109/l，white blood cell count ≥ 3×109/l, neutrophil count ≥ 2×109/l, hemoglobin ≥ 80 g/l exclusion criteria: * patients with cardiac pacemaker * patients with brain metastasis * patients with grade 3 hypertension or diabetic complication, severe cardiac and pulmonary dysfunction

Keywords: cancer ablation life information rehabilitation therapy